INMUNOTEK has participated in the 42nd Congress of the SEI (Spanish Society of Immunology), held in virtual format between March 24-26, with a Satellite Symposium entitled Vaccines based on trained immunity (TIbV) through mucosa. The MV130 model.

Dr. David Sancho (CNIC, Madrid) and Dr. Antonio Nieto (Hospital La Fe, Valencia) were the speakers who presented their experimental and clinical research, respectively, with MV130. The symposium was chaired by Dr. Silvia Sánchez-Ramón (Hospital Clínico, Madrid).

MV130 is a preparation of fully inactivated whole bacteria that induces trained immunity administered through the mucosa route (sublingual). Immune therapy with MV130 confers non-specific protection against various pathogens, including viruses, while promoting adaptive responses. MV130 is considered an illustrative example of TIbV (trained immunity-based vaccines).

---